BCAR3
Breast cancer anti-estrogen resistance protein 3
Also known as: AND-34, BCAR3_HUMAN, MIG7, NSP2, SH2D3B
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O75815
- Gene
- BCAR3
- Ensembl
- ENSG00000137936
- Chromosome
- 1
- Canonical length
- 825 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Plasma membrane,Centrosome,Cytosol
OverviewNCBI Gene
Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]
Canonical amino-acid sequenceUniProt
825 residues, UniProt reviewed canonical sequence.
>O75815|BCAR3
1 MAAGKFASLP RNMPVNHQFP LASSMDLLSS RSPLAEHRPD AYQDVSIHGT LPRKKKGPPP
61 IRSCDDFSHM GTLPHSKSPR QNSPVTQDGI QESPWQDRHG ETFTFRDPHL LDPTVEYVKF
121 SKERHIMDRT PEKLKKELEE ELLLSSEDLR SHAWYHGRIP RQVSENLVQR DGDFLVRDSL
181 SSPGNFVLTC QWKNLAQHFK INRTVLRLSE AYSRVQYQFE MESFDSIPGL VRCYVGNRRP
241 ISQQSGAIIF QPINRTVPLR CLEEHYGTSP GQAREGSLTK GRPDVAKRLS LTMGGVQARE
301 QNLPRGNLLR NKEKSGSQPA CLDHMQDRRA LSLKAHQSES YLPIGCKLPP QSSGVDTSPC
361 PNSPVFRTGS EPALSPAVVR RVSSDARAGE ALRGSDSQLC PKPPPKPCKV PFLKVPSSPS
421 AWLNSEANYC ELNPAFATGC GRGAKLPSCA QGSHTELLTA KQNEAPGPRN SGVNYLILDD
481 DDRERPWEPA AAQMEKGQWD KGEFVTPLLE TVSSFRPNEF ESKFLPPENK PLETAMLKRA
541 KELFTNNDPK VIAQHVLSMD CRVARILGVS EEMRRNMGVS SGLELITLPH GHQLRLDIIE
601 RHNTMAIGIA VDILGCTGTL EDRAATLSKI IQVAVELKDS MGDLYSFSAL MKALEMPQIT
661 RLEKTWTALR HQYTQTAILY EKQLKPFSKL LHEGRESTCV PPNNVSVPLL MPLVTLMERQ
721 AVTFEGTDMW EKNDQSCEIM LNHLATARFM AEAADSYRMN AERILAGFQP DEEMNEICKT
781 EFQMRLLWGS KGAQVNQTER YEKFNQILTA LSRKLEPPPV KQAELLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BCAR3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 29 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 29 nTPM
- skeletal muscle: 23 nTPM
- salivary gland: 21 nTPM
- tongue: 20 nTPM
- breast: 18 nTPM
- choroid plexus: 17 nTPM
Single-cell type
- podocytes: 338 nCPM
- endometrial secretory cells: 277 nCPM
- bergmann glia: 273 nCPM
- extravillous trophoblasts: 244 nCPM
- microglia: 206 nCPM
- choroid plexus epithelial cells: 204 nCPM
Immune cell
- basophil: 2 nTPM
- memory B-cell: 1.8 nTPM
- naive B-cell: 1.6 nTPM
- plasmacytoid DC: 0.7 nTPM
- intermediate monocyte: 0.4 nTPM
- myeloid DC: 0.3 nTPM
Brain region
- thalamus: 31 nTPM
- choroid plexus: 30 nTPM
- medulla oblongata: 30 nTPM
- midbrain: 29 nTPM
- basal ganglia: 29 nTPM
- cerebellum: 26 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about BCAR3.
Disease | ImmuneIEDB
Conditions an epitope on BCAR3 was assayed in.
- skin melanoma T cell
- melanoma T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.38
- gnomAD pLI
- 0.58
- gnomAD missense Z
- 0.3
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- endothelin receptor signaling pathway
- epidermal growth factor receptor signaling pathway
- insulin receptor signaling pathway
- lens morphogenesis in camera-type eye
- positive regulation of cell population proliferation
- positive regulation of GTPase activity
- positive regulation of MAPK cascade
- response to xenobiotic stimulus
- signal transduction
- small GTPase-mediated signal transduction
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- SH2 domain
- Ras guanine-nucleotide exchange factors catalytic domain
- Ras guanine nucleotide exchange factor domain superfamily
- SH2 domain superfamily
- Ras guanine-nucleotide exchange factor, catalytic domain superfamily
- SHEP1/BCAR3/NSP1, SH2 domain
- Adapter protein with SH2 and Ras-GEF domains
- SH2 domain
- RasGEF domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of BCAR3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BCAR3 as an antibody target. Whether an autoantibody or antibody against BCAR3 could matter depends on whether native BCAR3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BCAR3 is annotated at the cell surface, where native BCAR3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label BCAR3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...